Search Results

You are looking at 31 - 40 of 90 items for :

  • Medical and Health Sciences x
  • Refine by Access: Content accessible to me x
Clear All

, M. T. , Reed , S. , & Aggarwal , R. ( 2020 ). Culturally-informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder . Journal of Psychedelic Studies , 4 ( 1 ), 40 – 50 . https://doi.org/10

Open access

general public [Bachelor's thesis, University of Twente] . http://purl.utwente.nl/essays/82465 . Therapeutic Goods Administration ( 2023 , Feb 3). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Open access
Journal of Psychedelic Studies
Authors:
Sam Elias
,
Stephanie Spivak
,
Alexa Alverez
,
Alejandro Gili Olivares
,
Maria Ferrol
, and
Julian Paul Keenan

, K. H. , Heifets , B. D. , Hibicke , M. , Mitchell , J. , et al. ( 2021 ). Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine . The Journal of Neuroscience: The Official Journal of the

Open access
Journal of Psychedelic Studies
Authors:
Neşe Devenot
,
Brian A. Pace
,
Jason Slot
, and
Alan K. Davis

of harm in clinical trials of MDMA. The stakes of adequately communicating these risks to patients is high, especially since P-AT is anticipated as a treatment option for PTSD, which disproportionately impacts historically marginalized groups with

Open access

-schedule psilocybin and MDMA, allowing prescriptions by “authorised psychiatrists” for specific indications (PTSD and treatment-resistant depression, respectively) as of July 1, after an “aggressive” lobbying campaign led by Mind Medicine Australia (MMA) ( Blau

Open access

), lifetime phencyclidine (PCP) use (variable PCPFLAG; 0 = never used, 1 = ever used), lifetime 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) use (variable ECSFLAG for 2013–2014 and ECSTMOFLAG for 2015–2019; 0 = never used, 1 = ever used), and lifetime

Open access

studies showing no benefit and greater discontinuation rates (30%) compared to placebo (17%), hypothesized to be secondary to unreported adverse effects ( Friedman et al., 2007 ). Given these limitations, novel therapeutics, such as MDMA

Open access

World Religions , 3 ( 2019 ), 81 – 103 . http://doi.org/10.1556/2054.2019.012 . Roberts T. (Ed.). ( 2020 ). Psychedelics and spirituality: The sacred use of LSD, psilocybin, and MDMA for human transformation . Rochester, VT : Park Street Press

Open access

(MDMA/ecstasy) use (variable ECSFLAG for 2013–2014 and ECSTMOFLAG for 2015–2019; 0 = never used, 1 = ever used), and lifetime inhalant use (variable INHFLAG for 2013–2014 and INHALFLAG for 2015–2019; 0 = never used, 1 = ever used). All covariates were

Open access

psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA) and ketamine for treating psychological disorders, psilocybin for the treatment of depression has the most extensive and robust empirical support. As with many mental disorders, depression

Open access